AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02428569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREPARED Decision Support
Description: The PREPARED DVD presents patient and health care provider testimonials that characterize the pros and cons of different kidney replacement treatment options, including in-center hemodialysis, home hemodialysis, peritoneal dialysis, kidney transplant, and conservative management (i.e., no dialysis or transplant). The PREPARED book reinforces differences between the treatments by showing (in lay language) summaries of scientific evidence on treatment outcomes associated with each kidney replacement option.
Study NCT04766775 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Silver Diamine Fluoride
Description: Silver Diamine Fluoride (Riva Star) which contains silver, fluoride, ammonia and water.
Study NCT02110862 — intervention group
Intervention type: OTHER
Intervention: Transittime. Defecography
Study NCT02473367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir 1200 mg
Description: Two tablets of 600 mg raltegravir administered orally, once daily, over 5 days of Pre-treatment, and once at the start of Periods 1-4.
Study NCT02473367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TUMS
Description: Three tablets of TUMS Ultra Strength (US) 1000, taken orally, concomitantly with raltegravir in Period 2, and 12 hours after raltegravir in Period 4
Study NCT02219412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: 90 mg bid for 2 weeks
Study NCT02219412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 100mg Qd for 2 weeks.
Study NCT04331613 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAStem
Description: CAStem will be administered intravenously.
Study NCT02386293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Description: Double blind placebo controlled cross over trial to determine effectiveness of an angiotensin receptor blocker in obese hypertensive African American patients.
Study NCT02386293 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill made to look identical to irbesartan intervention.
Study NCT02473367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leader Antacid
Description: 20 mL Leader Antacid Maximum Strength (MS) taken orally 12 hours after raltegravir, in Period 3
Study NCT02225834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: treatment with atorvastatin 80 mg (once-daily) from admission day until discharge
Study NCT03525886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-74788
Description: Capsule, administered daily.
Study NCT04530643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HY209 0.3%
Description: 25 subjects will be assigned to drug (HY209 0.3% gel).
Study NCT03190460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Web-based cognitive training intervention targeting specific cognitive tasks. Subjects complete 3 training sessions per week with at least 24 hours in between sessions.
Study NCT03190460 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Technology-based Education
Description: Subjects complete 16 web-based educational modules on healthy aging content. Following each module, subjects complete a learning reflection.
Study NCT01389037 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Literacy-focused Self-help
Description: Weekly 2-hour sessions over 6 weeks followed by 12 month follow-up with home blood pressure self monitoring with telephone counseling by community health workers.
Study NCT01389037 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Delayed Intervention Control
Description: Given pamphlets on the importance of high blood pressure control and offered weekly workshops. This group will be offered the intervention at the conclusion of data collection.
Study NCT04530643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HY209 0.5%
Description: 25 subjects will be assigned to drug (HY209 0.5% gel).
Study NCT04530643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 25 subjects will be assigned to drug (Placebo).
Study NCT03565146 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PiQo4 Laser System
Description: PiQo4 Laser System for treatment of pigmented lesions
Study NCT01927900 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HMO
Study NCT00650975 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Thromboablation
Description: Laser Thromboablation using the Spectranetics CVX-300® excimer laser system
Study NCT00650975 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTCA (Direct Stenting)
Description: Balloon predilatation or Direct Stenting using conventional techniques according to local standards and device specific instructions for use
Study NCT00988910 — intervention group
Intervention type: DRUG
Intervention: EE30-DRSP (Yasmin, BAY86-5131)
Description: DRSP-containing combined oral contraceptives according to the normal routine praxis
Study NCT00988910 — intervention group
Intervention type: DRUG
Intervention: Other combined oral contraceptives
Description: Other combined oral contraceptives according to the normal routine praxis
Study NCT03870399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: The treatment to be used will be tamoxifen 20mg orally once daily.
Study NCT04248023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice Facilitation
Description: A practice facilitator will be assigned the each participating practice to assist with the development of a workflow, screening process, counseling resources, and referral resources for unhealthy alcohol use. Practices in control group will receive delayed intervention at 3 months after their matched cohort of practices.
Study NCT00269854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Description: Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 10 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2 and 6.
Study NCT00269854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab 10 mg/kg
Description: Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 5 mg/kg will be administered as infusion at Week 0, 2 and 6.
Study NCT00269854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab 20 mg/kg
Description: Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 20 mg/kg will be administered as infusion at Week 0, 2 and 6.
Study NCT01927900 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Glucose
Study NCT00269854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be adminstered at Week 0, 2 and 6.
Study NCT02274740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIXISENATIDE AVE0010
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study NCT02274740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT00656435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
Study NCT04007419 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Promoters and Organ Donation
Description: Promotoras de Donación is a highly engaging and interactive online learning experience, that accommodates multiple learning styles by incorporating a variety of pedagogic approaches. The module consists of two components: a didactic educational component and a skills-based communication component. The didactic component provides basic information about organ donation and transplantation and the need for donors in the Hispanic community, and addresses concerns about donation commonly held by older Latina. The skills-based component provides instruction on the key communication skills needed to effectively engage small groups in discussions about organ donation. This component is intended to build communication self-efficacy or confidence opening the discussion about donation, addressing concerns raised by mature and older women participating in the small group sessions, and promoting the act of donor registration using persuasive, but non-coercive language.
Study NCT02621294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measuring protein requirement
Description: a repeated measures design will be used on each athlete receiving eight graded intakes of protein on separate days in the form of AA in random order ranging from 0.2 to 3.5 g/(kg/d). Three baseline samples of breath and urine will be collected at 60, 45 and 30 min before the stable isotope is given orally. During a period of 150 to 270 min. after stable isotope ingestion, 5 breath and urine samples (every 30 min) will be collected to determine an isotopic plateau in breath and urine. The rate of release of 13CO2 from the oxidation of L-\[1-13C\] phenylalanine (F 13CO2) in breath will be measured and a breakpoint analysis will determine total protein requirement
Study NCT03270839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bonine 25Mg Chewable Tablet
Description: Motion sickness drug
Study NCT02127970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Description: Dalbavancin IV infusion over 30 minutes.
Study NCT00881647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment for Insomnia (CBT-I)
Description: CBT-I includes strategies and instructions targeted toward improving the quality of sleep and resolving problems falling and staying asleep
Study NCT01708135 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Use of smartphone app
Study NCT01922791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of probiotics, fish oil and their combination to placebo
Description: Double-blind randomized placebo controlled intervention
Study NCT01922791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Comparison of probiotics, fish oil and their combination to placebo
Description: Double-blind randomized placebo controlled intervention
Study NCT01303601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: Tablet The initial dose of olanzapine was 5mg daily and raised to 10 mg/day. After week 1, flexible dosing was allowed based on symptom response, up to 20 mg daily, as tolerated.~daily 6 weeks
Study NCT01303601 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Starch
Study NCT03676907 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: double layer suturation technique
Description: in our clinic uterine incision is sutured by single layer suturation technique routinely. in this arm, we will use double layer suturation technique which is also accepted as valid suturation technique in obstetrics and gynecology textbooks
Study NCT04010942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vit D
Description: Injection
Study NCT04010942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: tablets
Study NCT04010942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: tablets
Study NCT04010942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clomiphene
Description: Tablet
Study NCT04010942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene
Description: Tablet
Study NCT03200678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isokinetic assessment
Description: muscle torque assessement
Study NCT02127970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalbavancin-matching Placebo
Description: Dalbavancin-matching placebo IV infusion over 30 minutes.
Study NCT03200678 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: isokinetic assessment
Description: muscle torque assessement
Study NCT02045511 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Baltimore HEARS
Description: Tailored aural rehabilitation for participant and communication partner
Study NCT02045511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baltimore HEARS
Description: Tailored aural rehabilitation for participant and communication partner
Study NCT02045511 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Baltimore HEARS
Description: Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
Study NCT02045511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baltimore HEARS
Description: Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
Study NCT01814735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brown rice
Study NCT01814735 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brown rice
Study NCT01814735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White rice
Study NCT01814735 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: White rice
Study NCT01054638 — intervention group
Intervention type: DRUG
Intervention: HAART Treatment
Description: Using pharmacy records, identify all patients with HAART dispensing during baseline \& follow-up periods. For combination medications, classify person-time according to individual therapeutic components. HAART exposure classification by 1)any HAART exposure, 2)by HAART class, and 3)by specific nucleoside reverse transcriptase inhibitor exposure. Specific evaluation of fosamprenavir and amprenavir.~Subdivide person-time according to recent, past \& non-use of HAART. Person-time for each patient partitioned into exposure windows of Recent use(From start of dispensing to end of days supplied plus 6 months), Past use(From end of current use to end of follow-up or new HAART dispensing following recent use), \& Non-use(Time prior to first dispensing or all time for those who did not receive a dispensing).~Determine cumulative duration of exposure based on days supplied per dispensing per patient over the baseline \& follow-up periods: Non-use, Less than 1 yr, 1-2 yrs, More than 2yrs.
Study NCT04427969 — intervention group
Intervention type: BEHAVIORAL
Intervention: prone position
Description: to lay in prone position at least 12 hour in a day at ICU
Study NCT04278534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Complete radiation therapist-led education module using virtual reality
Study NCT02935673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lumicitabine
Description: Oral administration of lumicitabine as tablet.
Study NCT04278534 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive the usual verbal and written education materials
Study NCT04278534 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Complete radiation therapist-led face-to-face education module
Study NCT04278534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT04278534 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT00472134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: administered locally, 0.5% Bupivacaine (Marcaine Abbott Laboratories) or saline administered continuously for 48 hours at 2 mL/h.
Study NCT00472134 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: On-Q PainBuster pump
Description: local anesthetic (bupivacaine) administered via a pain relief system consisting of a 20 gauge soaker catheter attached to an elastomeric balloon pump that is capable of infusing a set volume of local anesthetic over a wide area of surgical site for 2 to 5 days
Study NCT01485523 — intervention group
Intervention type: OTHER
Intervention: Nasal provocation test
Description: TPNC to dust mite has an interest in the diagnosis of allergic rhinitis to dust mites when there remains a doubt due to the poly sensitization of the patient, or the lack of specific symptoms and / or the variability of the allergic symptoms during the year. However, this test has not completely validated with a study including a significant number of patients. That's why we plan a prospective single-center comparative open study with the main objective is to determine the sensitivity and specificity of conventional nasal provocation test (TPNC) in 120 patients of 18 to 65 years old with allergic rhinitis sensitized to dust mites and patients with allergic rhinitis not sensitized to dust mites. Our secondary objective is to compare the TPNC a faster TPN-called minute (60 minutes) and which allow a wider use. If we demonstrate the validity of TPN then it would become the gold standard needed to decide on a desensitisation to mites.
Study NCT00665184 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise via Negative Eccentric Work
Description: High intensity resistance training delivered 2-3 times per week for 12 weeks
Study NCT00665184 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care exercise training
Description: Evidence based exercise training (resistance training, aerobic training, flexibility training) 2-3 times per week for 12 weeks.
Study NCT00106782 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transcranial Electrical Polarization (TEP)
Study NCT02346084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc 300 mg tablet (PO) and Maraviroc 1% gel (PR and PV)
Description: Tablets: daily 300 mg oral maraviroc, Selzentry®,(MVC) for 8 consecutive days Gel: daily rectally administered 1% MVC gel for 8 daily consecutive days Female Participants - will receive an additional third regimen of daily vaginally administered MVC 1% gel for 8 consecutive days.~Each treatment regimen will be followed by a washout period of 14 to 21 days.~Participants will also be randomized to a biopsy sampling schedule (i.e., D8, D9, or D10 sampling).
Study NCT02357940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Product
Description: 1% Colloidal Oatmeal Balm
Study NCT01625247 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical drainage
Description: Postoperative abdominal drainage were connected to a 200-mL closed suction reservoir. The drainage was removed if there are drainage amount less than 20 mL and color was serous color.
Study NCT01625247 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical drainage
Description: Postoperative abdominal drainage were connected to a 200-mL closed suction reservoir. The drainage was removed if there are drainage amount less than 20 mL and color was serous color.
Study NCT02625610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Maintenance Phase: Intravenous (IV) infusion (10 mg/kg over 1 hour) once every 2 weeks.
Study NCT02625610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Induction Phase: Oxaliplatin was administered at a dose of 85 mg per square meter (mg/m\^2) as a continuous intravenous (IV) infusion on Day 1 along with leucovorin followed by 5-Fluorouracil every 2 weeks up to 12 weeks (or) Oxaliplatin at 130 mg/m\^2 IV on Day 1 along with capecitabine twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks up to 12 weeks.~Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.
Study NCT02442778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786-18
Description: 18 mg of Deudextromethorphan hydrobromide (d6-DM) and 4.9 mg of Quinidine sulfate (Q)
Study NCT02442778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as capsules.
Study NCT02442778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786-28
Description: 28 mg of d6-DM and 4.9 mg of Q
Study NCT02442778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786-42.63
Description: 42.63 mg of d6-DM and 4.9 mg of Q
Study NCT02242851 — intervention group
Intervention type: DRUG
Intervention: Telmisartan
Study NCT02264002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilobradine low dose 1
Study NCT02264002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilobradine low dose 2
Study NCT02264002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilobradine medium dose
Study NCT02264002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilobradine high dose 1
Study NCT02264002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilobradine high dose 2
Study NCT02264002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol succinate tablets
Study NCT02264002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03546751 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure
Description: This device delivers air pressure non invasively through a mask to stent open the upper airway to prevent obstruction during sleep. This is an FDA approved device that has been used for several decades to treat OSA.